Menu

Psychiatry

Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia

, ,

Once-Daily, Oral Product Candidate Showed Efficacy Equivalent to Olanzapine With Clinically Meaningful and Statistically Significant Lower Weight Gain in 300-Patient Study Company Plans to Initiate Pivotal Development Program in 2015 DUBLIN–(BUSINESS WIRE)–Jan. 7, 2015– Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase 2 […]

Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder

, ,

Safety and Tolerability Profile of ALKS 5461 Confirmed in FORWARD-1 Study, a Supportive Study in the FORWARD Phase 3 Pivotal Program Dosing Regimen Confirmed; Efficacy Data Showed Statistically Significant Improvements in Depression Scores Beginning at Week One and Continuing Through Eight-Week Treatment Period DUBLIN–(BUSINESS WIRE)–Jan. 6, 2015– Alkermes plc (NASDAQ: ALKS) today announced topline results […]

Forest Announces New FETZIMA™ (levomilnacipran ER capsules) Now Available in Pharmacies Throughout U.S.

, , , ,

NEW YORK– December 19, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major Depressive Disorder (MDD), also known as depression, in adults in July 2013. […]

Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders

, , , ,

Menlo Park, California and INGELHEIM, Germany, 18 December, 2013 – Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. […]

Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder

, , , ,

INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the […]

Forest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck

, , , ,

Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK —  December […]

Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine

, , , ,

NEW YORK & BUDAPEST, Hungary–  November 21, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or […]